Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.08T
Market cap1.08T
Price-Earnings ratio
39.16
Price-Earnings ratio39.16
Dividend yield
0.58%
Dividend yield0.58%
Average volume
2.05M
Average volume2.05M
High today
$1,157.60
High today$1,157.60
Low today
$1,140.30
Low today$1,140.30
Open price
$1,148.51
Open price$1,148.51
Volume
4.54M
Volume4.54M
52 Week high
$1,292.65
52 Week high$1,292.65
52 Week low
$712.05
52 Week low$712.05

Stock Snapshot

Eli Lilly(LLY) stock is priced at $1,152.95, giving the company a market capitalization of 1.08T. It carries a P/E multiple of 39.16 and pays a dividend yield of 0.58%.

On 2026-09-18, Eli Lilly(LLY) stock traded between a low of $1,140.30 and a high of $1,157.60. Shares are currently priced at $1,152.95, which is +1.1% above the low and -0.4% below the high.

The Eli Lilly(LLY)'s current trading volume is 4.54M, compared to an average daily volume of 2.05M.

During the past year, Eli Lilly(LLY) stock moved between $712.05 at its lowest and $1,292.65 at its peak.

During the past year, Eli Lilly(LLY) stock moved between $712.05 at its lowest and $1,292.65 at its peak.

LLY News

24/7 Wall St. 22m
Can Eli Lilly's Two-Drug Obesity Treatment Justify Its $1 Trillion Valuation?

Investing Can Eli Lilly’s Two-Drug Obesity Treatment Justify Its $1 Trillion Valuation? Eli Lilly stakes its trillion-dollar valuation on mid-stage data for a t...

Can Eli Lilly's Two-Drug Obesity Treatment Justify Its $1 Trillion Valuation?
Seeking Alpha 3h
Lilly wins full FDA approval for Inluriyo combo in breast cancer

Eli Lilly (LLY) on Friday announced that the U.S. FDA granted full approval for an all-oral regimen containing its estrogen receptor antagonist Inluriyo and kin...

Lilly wins full FDA approval for Inluriyo combo in breast cancer
TipRanks 5h
Lilly’s New FORAY: Vepugratinib Targets FGFR3-Driven Bladder Cancer

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Eli Lilly and Company is launching a Phase 2 study called FORAY to test vepugr...

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
9.4%
Sell
6.3%

More LLY News

The Motley Fool 7h
Better Buy for Cautious Investors: Eli Lilly vs Costco

Investors piled into growth stocks in recent years, particularly in the area of artificial intelligence (AI), and this movement offered the overall market enorm...

Better Buy for Cautious Investors: Eli Lilly vs Costco
TipRanks 10h
Eli Lilly price target raised to $1,284 from $1,273 at Guggenheim

Guggenheim analyst Seamus Fernandez raised the firm’s price target on Eli Lilly (LLY) to $1,284 from $1,273 and keeps a Buy rating on the shares. The firm is up...

Simply Wall St 1d
Is Eli Lilly A Bargain Following Fresh Obesity Drug Data?

Eli Lilly (LLY) just put fresh clinical data at the center of its story, highlighting new results for obesity and diabetes drugs and a genetic medicine collabor...

Is Eli Lilly A Bargain Following Fresh Obesity Drug Data?
The Motley Fool 2d
Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded?

Several years ago, Novo Nordisk (NVO -1.22%) -- which is now branding itself as Novo -- was performing so well that it was improving the entire economy of its h...

Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded?
Investor's Business Daily 2d
Arista Stock Holds Up Well Amid Weakness. Here's How To Capitalize.

These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Cloudflare Hits Buy Point 9/16/2026 Among the best stocks in earnings performance, highly...

Arista Stock Holds Up Well Amid Weakness. Here's How To Capitalize.
Benzinga 2d
Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab Ecosystem

Twist Bioscience Corporation (NASDAQ:TWST) on Wednesday announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli...

Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab Ecosystem
TipRanks 2d
Twist Bioscience enters agreement with Lilly TuneLab

Twist Bioscience Corporation (TWST) announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (L...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.